online casino bonus no deposit

Xsolla-Gründer Shurick Agapitov veröffentlicht Once Upon Tomorrow Fortnite Island: Eine bahnbrechende, immersive Erfahrung, die das Universum des Romans zum Leben erweckt

An online debate over foreign workers in tech shows tensions in Trump's political coalitionWall Street’s rally stalls as Nasdaq pulls back from its record

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ) for cancer, today announced that the first patient has been dosed in the Company's phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics ® targeting EGFR and LGR5. The phase 2, open-label trial will evaluate the safety and antitumor activity of petosemtamab monotherapy in 3L+ mCRC, post anti-EGFR therapy. To be eligible for enrollment, patients must lack certain mutations as detected in plasma by ctDNA NGS, including KRAS, NRAS. "We discovered petosemtamab from an unbiased screen of over 500 bispecific antibodies tested for the ability to inhibit cancer-derived, as compared to matched normal tissue derived, organoids. In preclinical CRC models, petosemtamab consistently demonstrates superior activity compared to cetuximab, a mainstay therapy in mCRC,” said John de Kruif Ph.D., Chief Technology Officer at Merus. "I am hopeful our unique platform technologies will translate into improved therapies for patients with heavily pretreated mCRC.” About Petosemtamab Petosemtamab, or MCLA-158, is a Biclonics ® low-fucose human full-length IgG1 antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5). Petosemtamab is designed to exhibit three independent mechanisms of action including inhibition of EGFR-dependent signaling, LGR5 binding leading to EGFR internalization and degradation in cancer cells, and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activity. About Merus N.V. Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics ® . Multiclonics ® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus' website and LinkedIn . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding the evaluation of petosemtamab in patients with mCRC, the clinical study design and objectives of the phase 2 study; and the hope that our unique platform technologies will translate into improved therapies for patients with heavily pretreated mCRC. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; impacts of the volatility in the global economy, including global instability, including the ongoing conflicts in Europe and the Middle East; we may not identify suitable Biclonics ® or bispecific antibody candidates under our collaborations or our collaborators may fail to perform adequately under our collaborations; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. These and other important factors discussed under the caption "Risk Factors” in our Quarterly Report on Form 10-Q for the period ended September 30, 2024, filed with the Securities and Exchange Commission, or SEC, on October 31, 2024, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Multiclonics ® , Biclonics ® and Triclonics ® are registered trademarks of Merus N.V. CONTACT: Investor and Media Inquiries: Sherri Spear Merus N.V. SVP Investor Relations and Strategic Communications 617-821-3246 [email protected] Kathleen Farren Merus N.V. Assoc. Director IR/Corp Comms 617-230-4165 [email protected]Kash Patel is Donald Trump ‘s pick to lead the Federal Bureau of Investigation, making him another member of the Trump Media & Technology Group DJT board to be selected for a position in the president-elect's next administration. What Happened: Patel is well-known as a loyal Trump supporter and, in the past, has spoken publicly about overhauling the FBI. Patel previously worked for Trump on the National Security Council in 2019. Patel also helped with the Pentagon transition effort from Trump to Biden, as reported by CNN . Along with his past experience working for the National Security Council, Patel also plays a role with Trump Media & Technology Group, which was co-founded by Trump. Patel serves as a director on the company’s board. Trump Media CEO Devin Nunes recently congratulated Patel on Trump's announcement. "An immensely talented lawyer and investigator with an unimpeachable devotion to our Constitution, Kash is a brilliant pick to serve as Director of the FBI," Nunes said in a press release. Nunes said he worked closely with Patel to "expose the saboteurs within the Intelligence Community who perpetuated the Russia collusion hoax." Patel previously served as an aide to Nunes when he was a U.S. representative and the top Republican on the House Intelligence Committee, CNN reported. Did You Know? Congress Is Making Huge Investments. Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool Patel's Wealth : A formal nomination of Patel as FBI director could shed more light on his finances and wealth, but right now, limited sources indicate how rich Trump’s anticipated nominee is likely to be. Since Trump left the White House after losing the 2020 election, Patel has remained close with the former president and has grown his wealth through merchandise related to Trump and positions with foundations. Patel was paid $130,000 last year as part of a consulting agreement between his company Trishul and Trump Media and Technology Group. Patel serves as an independent contractor of TMTG in exchange for an annual payment of $120,000 plus out-of-pocket reimbursements, according to a company filing . Patel is the author of a children's book trilogy called "The Plot Against the King." The book series features characters like King Donald, Sleepy Joe and Hillary Queenton, weaving plots about spreading lies to seize the throne and efforts to unseat "Comma-la-la-la-la" to reclaim it. Patel also founded the Kash Foundation, previously known as Fight With Kash, which provides financial assistance to active duty service members and veterans. Trump's leadership PAC has paid Patel over $300,000 since the start of 2023, the Associated Press reported. Patel has also promoted pills that claim to reverse the effects of the COVID-19 vaccine, Newsweek reported . Merchandise sold under the "K$H brand" includes playing cards and apparel that may also add to Patel's wealth and sources of income related to Trump. Patel also served as a producer on the song "Justice For All," which was penned by the Jan. 6 Prison Choir singing "The Star-Spangled Banner" mixed with Trump reciting the Pledge of Allegiance. What's Next: Like other nominees announced by Trump, no formal approval process has occurred yet as he awaits his January inauguration. Similar to other Cabinet nominations, a formal nomination of Patel by Trump would need to be approved and confirmed by the Senate. Prediction market Polymarket shows odds of 61% that Patel will be confirmed by the Senate. The market resolves as Yes and pays out at $1 per Yes contract if Patel is confirmed as the FBI Director by June 30, 2025. A rejection by the Senate, a withdrawal of Patel's nomination or an appointment approved during the Recess party without Senate confirmation will close at No and pay out $1 for No contracts and at zero for Yes contracts. On Polymarket, users can deposit funds using USDC USDC/USD via the Polygon MATIC/USD network, or directly from a crypto account with Ethereum ETH/USD . Like the 2024 election markets, the odds on potential Cabinet members are becoming hot betting markets on Polymarket. Read Next: Trump HHS Pick Robert F. Kennedy Jr.’s Wealth Comes From Family, Law Practice, Oil, Bitcoin Photo: Shutterstock © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Presentation Includes Discussion of Monetization of NurseMagicTM DETROIT, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Amesite Inc. AMST , a pioneering technology company specializing in the development and marketing of B2C and B2B AI-driven solutions, announced today it will release an end of year video shareholder update to its website today, December 23, 2024 at 3:00 pm ET. The presentation will be available to shareholders here: https://ir.amesite.com/news-events/media . As part of the update, Amesite's CEO, Dr. Ann Marie Sastry, will review: NurseMagicTM B2C and B2B Offerings and Revenue Growth NurseMagicTM Marketing, Onboarding and Projected Profitability Metrics Company Infrastructure and Ability to Scale Users Financial Standing About Amesite Inc. Amesite Inc. AMST is a pioneering technology company specializing in the development and marketing of B2C and B2B AI-driven solutions. Leveraging its proprietary AI infrastructure, Amesite offers cutting-edge applications that cater to both individual and professional needs. NurseMagicTM, the company's mobile app for health and care professionals, streamlines creation of nursing notes and documentation tasks, enhances patient communication, and offers personalized guidance to nurses on patient care, medications, and handling challenging workplace situations. Forward Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company, the Company's planned online machine learning platform, the Company's business plans, any future commercialization of the Company's online learning solutions, potential customers, business objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its planned platform are set forth in the Company's filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact MJ Clyburn TraDigital IR clyburn@tradigitalir.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.ATLANTA (AP) — Even the woeful NFC South, where no team has a winning record, can't hide the Atlanta Falcons' offensive shortcomings. Three straight setbacks, including an ugly 17-13 loss to the Los Angeles Chargers, has left the Falcons 6-6 and feeling the pressure. Only a tiebreaker advantage over Tampa Bay has kept the Falcons atop the division. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.